By a News Reporter-Staff News Editor at Obesity & Diabetes Week -- Investigators publish new report on Hematology. According to news reporting originating from Columbus, Ohio, by NewsRx correspondents, research stated, "Nanofiber-expanded human umbilical cord blood-derived CD34(+) cell therapy has been shown to have potential applications for peripheral and myocardial ischaemic diseases. However, the efficacies of expanded CD34(+) cell therapy for treating cutaneous wounds and its mechanisms of action have yet to be established."
Our news editors obtained a quote from the research from Ohio State University, "Using an excisional wound model in non-obese diabetic/severe combined immune deficient mice, we show herein that CD34(+) cells accelerate the wound-healing process by enhancing collagen synthesis, and increasing fibroblast cell migration within the wound bed. Concomitantly, reduced levels of matrix metalloproteinase (MMPs) such as MMP1, MMP3, MMP9 and MMP13 were detected in the wound beds of animals treated with CD34(+) cells compared with vehicle-treated controls. CD34(+) cells were found to mediate enhanced migration and proliferation of dermal fibroblast cells in vitro. Moreover, CD34(+) cells secrete collagen in a serum-deprived environment. In mechanistic studies, co-culture of CD34(+) cells with primary skin fibroblasts increased the expression of collagen1A1, a component of type 1 collagen, and decreased the expression of MMP1 in fibroblast cells in the presence of a proteasome inhibitor. Finally, CD34(+) cell-mediated functions were transcriptionally regulated by the c-Jun N-terminal kinases pathway."
According to the news editors, the research concluded: "Collectively, these data provide evidence of therapeutic efficacy and a novel mechanism of nanofiber-expanded CD34(+) cell-mediated accelerated wound healing."
For more information on this research see: Nanofiber-expanded human umbilical cord blood-derived CD34(+) cell therapy accelerates cutaneous wound closure in NOD/SCID mice. Journal of Cellular and Molecular Medicine, 2014;18(4):685-697. Journal of Cellular and Molecular Medicine can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Journal of Cellular and Molecular Medicine - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1582-4934)
The news editors report that additional information may be obtained by contacting S. Kanji, Ohio State University, Davis Heart & Lung Res Inst, Wexner Med Center, Stem Cell Res Lab, Columbus, OH 43210, United States. Additional authors for this research include M. Das, R. Aggarwal, J.W. Lu, M. Joseph, V.J. Pompili and H. Das (see also Hematology).
Keywords for this news article include: Ohio, Biotechnology, Columbus, Collagen, Stem Cell, Cord Blood, Hematology, Fibroblasts, Cell Therapy, Therapeutics, United States, Blood Transfusion, Biological Therapy, Transfusion Medicine, Connective Tissue Cells, North and Central America, Extracellular Matrix Proteins
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC